{"id":"NCT02301156","sponsor":"TG Therapeutics, Inc.","briefTitle":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","officialTitle":"A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-27","primaryCompletion":"2020-04-01","completion":"2020-04-01","firstPosted":"2014-11-25","resultsPosted":"2022-05-20","lastUpdate":"2022-05-20"},"enrollment":126,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Ublituximab","otherNames":["TG-1101"]},{"type":"DRUG","name":"Ibrutinib","otherNames":["IMBRUVICA"]}],"arms":[{"label":"Ublituximab + Ibrutinib","type":"EXPERIMENTAL"},{"label":"Ibrutinib","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluates the effect of the addition of ublituximab, a novel monoclonal antibody, to ibrutinib compared to ibrutinib alone on antitumor activity, as measured by the overall response rate (ORR = CR \\[complete response\\] + PR \\[partial response\\]) in previously treated Chronic Lymphocytic Leukemia (CLL) participants with high-risk cytogenetic features. Half of the participants will receive ublituximab in combination with ibrutinib, while the other half will receive ibrutinib alone.","primaryOutcome":{"measure":"Overall Response Rate (ORR)","timeFrame":"Up to 62 months","effectByArm":[{"arm":"Ublituximab + Ibrutinib","deltaMin":84.4,"sd":null},{"arm":"Ibrutinib","deltaMin":69.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0463"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":88,"countries":["United States","Israel"]},"refs":{"pmids":["33631112"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":59},"commonTop":["Diarrhoea","Fatigue","Nausea","Cough","Headache"]}}